Kelly Abernathy

Kelly is the Vice President of Clinical Development. Kelly has 20 years of experience managing Phase I – IV clinical development programs in both adult and adolescent populations, with the majority of those programs involving products for the treatment of CNS diseases and disorders. Prior to joining QuatroBio, Kelly was the Director of Clinical Affairs at Aerial BioPharma, a successful drug development company that out-licensed its lead product for excessive daytime sleepiness in narcolepsy to Jazz Pharmaceuticals in 2014. Kelly was previously the Manager of Clinical Affairs at Neuronex Pharmaceuticals, a specialty drug development company focused on developing treatments for patients with certain seizure disorders, acquired by Acorda Therapeutics in 2012. In addition, Kelly was an original member of the management team at Addrenex Pharmaceuticals, a pharmaceutical development company, sold to Shionogi Pharma in 2009. While at Addrenex, Kelly managed the clinical program and NDA submission of the company’s lead product for ADHD. Kelly was previously Section Head of Clinical Operations at Lineberry Research Associates, a contract research organization, where she managed clinical trials for a variety of pharmaceutical companies, from small start-up to large pharma, and provided line leadership to a department of clinical trial project managers and research associates. Kelly graduated magna cum laude with a BS in biology, minoring in chemistry from Meredith College in Raleigh, NC.